University of North Florida

UNF Digital Commons
UNF Graduate Theses and Dissertations

Student Scholarship

2022

Identification and Characterization of the TSSK6 Activating Cochaperone (TSACC) Gene in Skeletal Muscle
Tala Shourbagi Tello
n01182320@unf.edu

Follow this and additional works at: https://digitalcommons.unf.edu/etd
Part of the Musculoskeletal Diseases Commons

Suggested Citation
Shourbagi Tello, Tala, "Identification and Characterization of the TSSK6 Activating Co-chaperone (TSACC)
Gene in Skeletal Muscle" (2022). UNF Graduate Theses and Dissertations. 1140.
https://digitalcommons.unf.edu/etd/1140

This Master's Thesis is brought to you for free and open
access by the Student Scholarship at UNF Digital
Commons. It has been accepted for inclusion in UNF
Graduate Theses and Dissertations by an authorized
administrator of UNF Digital Commons. For more
information, please contact Digital Projects.
© 2022 All Rights Reserved

Identification and Characterization of the TSSK6 Activating Co-chaperone (TSACC) Gene in
Skeletal Muscle
By
Tala Shourbagi Tello

A thesis submitted to the Department of Biology
in partial fulfillment of the requirements for the degree of
Master of Science in Biology
UNIVERSITY OF NORTH FLORIDA
COLLEGE OF ARTS AND SCIENCES
July 2022
CERTIFICATE OF APPROVAL

The thesis “Identification and Characterization of the TSSK6 Activating Co-chaperone (TSACC)
Gene in Skeletal Muscle” submitted by Tala Tello

Approved by the thesis committee:

Date

_____________________________
Dr. David Waddell, Ph.D.
Committee Chairperson

___________________

______________________________
Dr. Frank Smith, Ph.D.

___________________

______________________________
Dr. John Hatle, Ph.D.

___________________

ii

Table of Contents
Part I: Introduction and Background
Skeletal muscle and skeletal muscle atrophy

1

The Ubiquitin Proteasome System (UPS)

1

Differential Gene Expression in Response to Denervation-induced Atrophy

2

Myogenic Regulatory Factors (MRFs) are upregulated during Muscle Differentiation and
Atrophy

6

Mitogen Activated Protein Kinase (MAPK) Signaling

7

AKT signaling cascade

8

Part II: Identification and characterization of TSSK6 Activating Co-chaperone (Tsacc) in
skeletal muscle
Overview of Tsacc

10

Materials and Methods

10

Results

17

Tsacc is induced during neurogenic atrophy

17

Tsacc expression is regulated by Myogenic Regulatory Factors

18

Tsacc is alternatively spliced in skeletal muscle cells

19

Tsacc is upregulated during muscle cell differentiation

21

Tsacc full length (FL) and Tsacc-novel display distinct localization patterns in muscle cells

22

Ectopic expression of Tsacc-FL attenuates muscle cell differentiation while Tsacc-novel
overexpression has no effect on muscle cell differentiation

24

Overexpression of Tsacc may inhibit AKT activation

27

Discussion

29

Future Directions

31

Characterize the role of Tsacc in the MAP kinase signaling pathway

31

References

34

iii

List of Figures
Figure 1. Schematic of the ubiquitin proteasome system

2

Figure 2. MuRF1 and MAFbx are upregulated during muscle atrophy

3

Figure 3. Transcriptional activity of the MuRF1 gene locus and MAFbx in WT and
MuRF1 KO mice post-denervation

5

Figure 4. Process of muscle cell development is controlled by myogenic regulatory factors
(MRFs).

7

Figure 5. Schematic of the MAPK signaling pathways

8

Figure 6. The insulin-like growth factor 1 (IGF1)-Akt pathway controls muscle growth via
mammalian target of rapamycin (mTOR) and FoxO proteins

9

Figure 7. Tsacc is induced in response to denervation-induced skeletal muscle atrophy

18

Figure 8. Cloning and analysis of the proximal regulatory region of the Tsacc gene locus

20

Figure 9. Schematic of the validated Tsacc transcript and a newly discovered Tsacc novel
transcript

20

Figure 10. qPCR analysis of Tsacc expression in C2C12 cells

22

Figure 11. Tsacc-FL localizes to the cytoplasm of muscle cells

23

Figure 12. Tsacc-novel localizes to both the cytoplasm and nucleus of muscle cells

23

Figure 13. Validation of myc-tagged Tsacc-FL and Tsacc-novel overexpression in
C2C12 cells

24

Figure 14. Ectopic expression of Tsacc-FL attenuates muscle cell differentiation

26

Figure 15. Ectopic expression of Tsacc-novel does not appear to affect muscle cell
differentiation

27

Figure 16. Ectopic expression of either Tsacc-FL or Tsacc-Novel appears to inhibit AKT
activation in muscle cells

26

Figure 17. Ectopic expression of Tsacc-novel appears to upregulate the ERK1/2 branch of the
MAPK signaling cascade
32

iv

List of Tables
Table 1. List of primers used in this study

12

Table 2. List of antibodies used in this study

16

v

Abstract
Skeletal muscle atrophy is defined as a decrease in muscle size and occurs due to disparate
physiological conditions, including aging, immobilization, and corticosteroid exposure. TSSK6
activating co-chaperone (TSACC) was identified as a gene that is significantly upregulated in
skeletal muscle in response to denervation. To confirm Tsacc expression in skeletal muscle, the
Tsacc cDNA was cloned from cultured myoblast cells leading to the discovery of a novel
alternative splice-variant that is 49 amino acids shorter than the known full-length transcript.
Quantitative PCR (qPCR) confirmed that Tsacc is expressed in skeletal muscle with expression
increasing as muscle cells undergo differentiation. Characterization of Tsacc transcriptional
activity revealed that Tsacc gene activity is modulated by myogenic regulatory factors (MRFs)
and is significantly induced by MyoD. Moreover, sub-cellular localization was assessed by
confocal microscopy, which showed that the two Tsacc proteins produced by the two alternatively
spliced transcripts had distinct localization patterns. Tsacc-FL localized exclusively to the
cytoplasm of muscle cells while Tsacc-novel localized diffusely within the cell, appearing in both
the nucleus and cytoplasm of muscle cells. Finally, Western blot analysis revealed that ectopic
expression of the full-length Tsacc transcript in C2C12 resulted in significant inhibition of conical
markers of muscle differentiation, including MyHC and myogenin while the novel Tsacc transcript
did not. The impact of Tsacc on the AKT signaling pathway, which is known to participate in the
regulation of muscle size, was also assessed. Overexpression of either the full-length or novel
Tsacc transcript was found to modulate the AKT signaling pathway in cultured muscle cells.
Understanding the role of Tsacc will further our understanding of the molecular and genetic
mechanisms of the muscle wasting and potentially provide new therapeutic targets for mitigating
the negative outcomes associated with muscle atrophy.
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Part I: Introduction and Background
Skeletal muscle and skeletal muscle atrophy
Skeletal muscle is a dynamic tissue that has the ability to respond to physiological and
pathophysiological stimuli by differential regulation of protein synthesis and protein turnover
pathways. An imbalance between protein synthesis and protein degradation can lead to abnormal
muscle mass resulting in gain or loss of muscle mass. These two conditions are known as
hypertrophy and atrophy, respectively. Physical activity such as resistance training can lead to
muscle hypertrophy while conditions such as cachexia, inflammation, aging, and increased
corticosteroid levels can all lead to muscle atrophy.
Muscle atrophy is defined as the reduction in muscle mass and contractile strength. Proteolysis,
the breakdown of proteins, is an essential process for cell survival allowing the body to get rid of
damaged, defective, or unneeded proteins. Yet when protein degradation outweighs protein
synthesis, a decrease in muscle mass occurs (Egerman and Glass, 2014). Two main proteolytic
systems that control this protein turnover in cells are the ubiquitin proteasome system (UPS) and
the autophagy lysosome system (ALS).
The Ubiquitin Proteasome System (UPS)
The ubiquitin proteasome system (UPS) utilizes three enzymes that function in conjunction
with the 26S proteasome. These three enzymes are known as the E1 ubiquitin-activating enzyme,
the E2 ubiquitin-conjugating enzyme, and the E3 ubiquitin ligase. The UPS pathway is initiated
by the activation of a 76-amino acid ubiquitin protein by an E1 enzyme, leading to the formation
of a thioester bond between the carboxyl terminus of ubiquitin and the cysteine of the active site
on the E1 (Fig. 1). The activated ubiquitin is then transferred to the E2 enzyme, which is then
ligated to the target substrate to tag it for degradation (McKinnell, 2004). The transfer of ubiquitin

is achieved when the E3 ligase simultaneously binds with an E2 and a specific target substrate
(McKinnell, 2004). Therefore, the E3 ligase is generally believed to provide the selectivity and
specificity of the many different targets of the UPS pathway. To promote substrate turnover, the
conjugation and ubiquitin transfer cycles continue until the substrate accumulates four or more
molecules of ubiquitin, which then triggers degradation by the 26s proteasome (Fig. 1).

Figure 1: Schematic of the ubiquitin proteasome system. The E1 ubiquitin activating enzyme,
E2 ubiquitin conjugating enzyme, and E3 ubiquitin ligase form a pathway to ubiquitinate
substrates for degradation by the 26s proteasome (Adapted from Egerman, 2014).
Differential Gene Expression in Response to Denervation-induced Atrophy
Because the specificity of protein degradation is dictated by the E3 ubiquitin ligases,
identification of E3 ubiquitin ligases is of importance to better understand the muscle atrophy
pathway. To identify potential atrophy promoting genes, Bodine et al. subjected rats to different
atrophy stimuli including denervation, immobilization, and hind limb suspension. Interestingly,
two genes that encode for ubiquitin E3 ligases were found to be upregulated in all three models of
atrophy and were named Muscle RING Finger 1 (MuRF1) and Muscle Atrophy F-box (MAFbx)
(Fig.2). To further evaluate the function of these two genes, MAFbx and MuRF1 knockout (KO)
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mice were generated through β-galactosidase lacZ cassette insertion into the genomic region of
each gene. MAFbx-null and MuRF1-null mice were then subjected to denervation of the tibialis
and gastrocnemius muscles for 14 days and compared to wild-type mice. The MuRF1-null mice
showed 36% muscle sparing while the MAFbx-null mice showed 56% muscle sparing (Bodine et
al., 2001). Even though the MAFbx knockouts showed a greater percentage of muscle sparing, the
MuRF1 knockouts displayed greater muscle integrity, making MuRF1 the leading candidate for
therapeutic intervention of muscle atrophy (Furlow et al., 2013).

Figure 2. MuRF1 and MAFbx are upregulated during muscle atrophy. Northern blot
displaying mRNA expression of MuRF1 and MAFbx in muscle tissue of rats subjected to atrophy
induction by immobilization, denervation, and hind limb suspension. Increased expression is
observed at day 1 and reaches a peak at day 3 post-denervation (Bodine et al, 2001).
MuRF1 is a member of the TRIM family, which is composed of about 80 E3 ubiquitin ligases
that are characterized by a RING domain, a zinc-finger B-box domain, and a leucine-rich coiledcoil domain (Bodine and Baher, 2014). The RING domain of E3 ubiquitin ligases has a role in
bringing the substrate protein and ubiquitin from the E2 into contact. The RING domain, which
consists of important cysteine and histidine residues is believed to perform the catalytic activity of
MuRF1, while the zinc-finger B-box domain is suggested to function in binding to DNA or other
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proteins (Ikeda and Inoue, 2013). While it is clear that MurF1 plays an important role in the skeletal
muscle atrophy, the exact molecular function of this E3 ligase is not well understood and very few
validated targets have been identified (Bodine and Baehr, 2014). Moreover, the lack of clearly
identified protein targets has led to further evaluation of MuRF1’s specific role in skeletal muscle
atrophy.
To better understand MuRF1’s role in skeletal muscle, Furlow et al.,2013 conducted a genomewide transcriptomic analysis comparing MuRF1 knockout (KO) mice with wild-type (WT) mice
following denervation for 3 and 14 days. The goal of the microarray study was to identify genes
that are differentially regulated in WT mice compared to atrophy resistant MuRF1-KO mice. The
MuRF1-null mice were generated by insertion of a β-gal-encoding lacZ cassette into the MuRF1
gene locus insertion to disrupt the MuRF1 gene and introduce β-galactosidase when the MuRF1
promoter is active, allowing for assessment of endogenous MuRF1 promoter activity without the
effect of the functional MuRF1 gene. Gastrocnemius muscle tissue was isolated at 3- and 14-days
post-denervation and a genome wide microarray was conducted (Furlow et al., 2013). In order to
confirm knockout, MuRF1 expression in MuRF1 KO mice was evaluated and found to be missing
as expected. In contrast, the WT mice displayed an increase in expression of MuRF1 at 3 days
post-denervation that returned to baseline by 14 days post-denervation (Fig 3A). Interestingly, in
the KO mice β-galactosidase expression was elevated at day 3 post-denervation and remained
elevated at day 14 post-denervation, suggesting that MuRF1 might be negatively regulating its
own expression (Fig 3B).
MAFbx expression was also evaluated in the WT mice in response to denervation and was
found to have increased expression at day 3 post-denervation and a return to baseline by day 14
(Fig 3C). However, in the MuRF1 KO mice, MAFbx expression was elevated at day 3 post-
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denervation and remained elevated at day 14 post-denervation, suggesting that MuRF1 may not
only be negatively regulating itself but also negatively regulating MAFbx expression (Fig 3D).

Figure 3. Transcriptional activity of the MuRF1 gene locus and MAFbx in WT and MuRF1
KO mice post-denervation. (A) Denervated WT mice show an increase in MuRF1 gene
expression at day 3 (3D) but returns to baseline at day 14 (14D) post-denervation. (B) Denervated
KO mice show an increase in β-galactosidase expression, which is under the control of the MuRF1
promoter, at day 3 and expression remained elevated at day 14 post-denervation. (C) Denervated
WT mice show an increase in MAFbx gene expression at day 3 (3D) but a return to baseline levels
by day 14 (14D) post-denervation. (D) Denervated MuRF1 KO mice showed increased expression
in MAFbx at day 3 (3D) that remained elevated at day 14 (14D) (Furlow et al, 2013).
Moreover, beyond MuRF1 and MAFbx, our lab has also identified and characterized a
number of other differentially expressed genes in MuRF1-null mice in response to denervation,
including Ttc389, Dusp4, Dupd1/Dusp29, Fam83d, and Zfp593 (Hayes et al, 2019, Haddock et al,
2019, Cooper et al, 2020a, Cooper et al, 2020b, Lynch et al, 2019). In addition to genes
differentially expressed in MuRF1-null mice, the microarray study also identified hundreds of
genes that were differentially expressed in mice undergoing neurogenic atrophy regardless of
genotype. Many of these differentially expressed genes exhibited a range of different functions,
5

with some known to play a role in muscle structure and function, while others have been linked to
metabolic pathways and signal transduction cascades. Importantly, a subset of genes induced in
response to denervation have not been previously characterized in skeletal muscle or any other
tissue, including TSSK6 Activating Co-chaperone (TSACC), which is the focus of this study.
Myogenic regulatory factors (MRFs) are upregulated during muscle differentiation and atrophy
Myogenesis, the process of muscle cell development is controlled through myogenic regulatory
factors (MRFs). MRFs are a family of muscle specific factors that control both pre-natal and postnatal myogenesis. During embryonic development, mesodermal cells generate myogenic cells that
ultimately give rise to differentiated skeletal muscle tissue. Yet, a subset of these myogenic cells
form satellite cells instead. These satellite cells acts as adult stem cells and are responsible for
muscle regeneration and development after birth. Upon injury, satellite cells begin to proliferate
and divide into myoblasts and then differentiate into myotubes, giving rise to mature muscle tissue
(Fig. 4). MRFs regulate this highly orchestrated process and function by interacting with coactivators and co-repressors at the promoter regions of muscle-specific genes. (Hettmer and
Wagers, 2010). The structure of MRFs is characterized by the presence of a basic helix-loop-helix
domain (bHLH) that allows binding with E-box consensus sequences (5’-CANNTG-3’) located
within the promoters of many muscle-specific genes.
MyoD and myogenin are two MRFs that have been shown to be upregulated during neurogenic
atrophy (Furlow et al, 2013). MyoD acts as a marker of myogenic commitment to skeletal muscle
and plays a role in early myogenesis by promoting myoblast proliferation, while myogenin plays
a key role in late myogenesis, promoting muscle cell differentiation and the fusion of myoblast
into myotubes (Hindi et al, 2017). Additionally, myogenin is essential for full induction of MuRF1
and MAFbx under neurogenic atrophy conditions and previous studies have shown that the
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deletion of myogenin leads to lower levels of MuRF1 and MAFbx expression and resistance to
muscle wasting in mice subjected to denervation (Dilworth, Singh, 2013).

Figure 4. Process of muscle cell development is controlled by myogenic regulatory factors
(MRFs). MyoD and myogenin are two MRFs that play a critical role in muscle cell proliferation
and differentiation, respectively (Hettmer and Wagers, 2010)
Mitogen-activated protein kinase (MAPK) signaling
Mitogen-activated protein kinase (MAPK) signaling plays a critical role in growth and repair
of muscle tissue upon injury. It has been shown that MAPK signaling is important for muscle cell
differentiation, specifically complete differentiation, and fusion of myoblasts into myotubes
(Bennett and Tonks, 1997). MAPK signaling involves four pathways including extracellular
signal-related kinase 1/2 (ERK1/2), p38, c-Jun N-terminal kinase (JNK), and ERK5, which have
all been implicated in muscle cell proliferation, migration, differentiation, and fusion (Fig. 5). The
ERK1/2 signaling pathway is active during myoblast proliferation, decreases as cells differentiate
and then peaks again at terminal differentiation to induce myoblast fusion into myotubes (Bennett
and Tonk, 1997). The p38 branch is activated during muscle cell differentiation and is required for
myotube formation, while JNK signaling negatively regulates muscle cell differentiation and is
downregulated in late myogenesis (Xie et al., 2018). ERK5 has been implicated in stimulation of
myoblast fusion and when blocked, myoblast fusion and the formation of multinucleated myotubes
7

is inhibited (Hindi et al., 2013). These pathways are highly regulated and may function
concurrently during muscle development and repair following injury (Hindi et al., 2013).

Figure 5. Schematic of the MAPK signaling pathways (Wang and Xia, 2012).
AKT signaling cascade
MAPK is not the only signaling pathway involved in muscle growth and myogenesis. The
serine/threonine kinase AKT/protein kinase B is activated by insulin-like growth factor (IGF) and
functions to activate the expression of proteins related to protein synthesis, such as mTOR.
Moreover, activated AKT suppresses the activity of the FoxO family of transcription factors,
which are known to promote skeletal muscle atrophy. Thus, AKT is essential in regulating both
protein synthesis as well as protein degradation pathways, which work in tandem to regulate
muscle mass (Egerman and Glass, 2014) (Fig.6).
AKT has been found to stimulate protein synthesis via two branches. The first branch is through
the activation of mTOR. The activation of mTOR leads to the phosphorylation of its downstream
target 4E-BP1. Phosphorylated 4E-BP1 is then no longer able to bind and inhibit the eIF4E
initiation factor that is essential for protein translation, which leads to an increase in protein
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translation levels within muscle cells. The second mechanism is through AKT phosphorylation of
Glycogen synthase kinase 3β (GSK-3β). GSK-3β is constitutively active and functions by
inhibiting protein synthesis (Schiaffino and Mammucari, 2011). The phosphorylation of GSK-3β
leads to its inactivation and inability to phosphorylate and inhibit downstream protein targets
related to protein synthesis.
AKT inhibits protein degradation by phosphorylating and repressing transcription factors
of the FoxO family, which are required for transcriptional regulation of the E3 ubiquitin ligases
MuRF1 and MAFbx (Stitt et al., 2004). Thus, AKT indirectly results in the inhibition of the
transcriptional activity of both MuRF1 and MAFbx. Due to the role of AKT in regulating identified
mediators of skeletal muscle cell function, genes that potentially regulate the activation of AKT
are of interest for elucidating the mechanisms by which the atrophy cascade proceeds.

Figure 6. The insulin-like growth factor 1(IGF1)-Akt pathway controls muscle growth via
mammalian target of rapamycin (mTOR) and FoxO proteins. (Schiaffino and Mammucari,
2011).
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Identification and characterization of TSSK6 Activating Co-chaperone (TSACC) in skeletal
muscle
Overview
TSSK6 Activating Co-chaperone (Tsacc) is a protein coding gene that is exclusively found in
mammals. Previous studies have shown that Tsacc plays an important role as a co-chaperone by
binding to HSP70 and facilitating HSP90 mediated TSSK6 activation (Jha et al., 2010). TSKK6
activation appears to be necessary for male fertility in mammals and it has been shown that the
male infertility phenotype has been associated with a mutation or absence of the Tsacc gene in
maturing spermatids (Jha et al., 2017). Even though most studies are concerned with Tsacc’s role
on spermatogenesis, one study found that Tsacc may also play an important role in regulating cell
proliferation, apoptosis, and differentiation (Capra, 2006). While there is some data on the putative
functions of Tsacc, the exact role of this gene in skeletal muscle has not been previously
investigated. Therefore, the goal of this study was to characterize and elucidate the potential
function of Tsacc in skeletal muscle.
Materials and Methods
Animals
There were no animal experiments related to the current study conducted at the University of
North Florida; however, the sex, age range, strain, and treatment conditions of the animals used
for the Illumina microarray studies, as well as the IUCAC approvals, have been previously
described (Furlow et al., 2013)
Cell Culture
C2C12 mouse myoblasts were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM)
(Thermo Fischer Scientific, Waltham, MA) supplemented with 10% Fetal Bovine Serum (FBS)
(GE Healthcare HyClone Laboratories, Logan, UT), 1X Penicillin/Streptomycin and Gentamicin
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(Thermo Fischer Scientific, Waltham, MA), and non-essential amino acids (GE Healthcare
HyClone Laboratories, Logan, UT). Cells were maintained in a humidified chamber at 37°C and
5% CO2. Cells were grown to 100% confluency and switched to DMEM supplemented with 2%
serum to induce differentiation.
RNA isolation and complementary DNA synthesis
Total RNA was isolated from C2C12 myoblasts and myotubes using the RNeasy Mini Kit
(Qiagen, Valencia, CA) following the manufacturer’s instructions. Isolated RNA was used to
synthesize complementary DNA (cDNA) using a PolyT primer and Moloney Murine Leukemia
Virus (M-MLV) Reverse Transcriptase according to the manufacturer’s instructions (Thermo
Fisher Scientific, Waltham, MA).
Amplification and cloning of the Tsacc cDNA
For the amplification of the Tsacc cDNA, gene-specific primer pairs were designed (Table 1)
using the gene sequence for murine Tsacc (GenBank accession number: NM_029801.2) and mixed
with template DNA generated by reverse transcription described above according to the
manufacturer’s recommendation (ThermoFisher Scientific, Waltham, MA). Tsacc cDNA was
subcloned into the EcoRI and XbaI sites of the pcDNA3 (+) (ThermoFisher Scientific, Waltham,
MA) and pCS2(+)-myc expression plasmids. The cDNA of Tsacc was also fused in frame with
GFP by cloning into the EcoRI and XbaI sites of the pEGFP-C1 expression plasmid (Clontech,
Mountain View, CA).

Table 1. Primer Sequences Used in This Study
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Primer Name

Primer Sequence (5’ to 3’)

Tsacc-cDNA-F

GCGAATTCCAAGATGGAGCAGCACACTAGTAACC

Tsacc-cDNA-R

GCTCTAGACAGCTCATTTATGGAATTGGGGCAGG

Tsacc-qPCR-F1

GAAGCTCTGTTTTGTCCATCGG

Tsacc-qPCR-R1

GTAGGGTTACTAGTGTGCTGC

Tsacc-qPCR-F2

CTTGACCATCCAGACAAAGC

Tsacc-qPCR-R2

CTATCTGTCGTTGAGCAAGC

Tsacc-qPCR-F3

TCTTCAGGAGCTGGTCAGAAG

Tsacc-Pro1000-F

GCACGCGTGTGCTCTTTACTGAGATGAGTGGCG

Tsacc-Pro500-F

GCACGCGTGAGCTTGGTCCAAGGCGAAAAGACC

Tsacc-Pro-R

GCGAATTCCCTACAGCATTAATCCAAAGCCTCC

Promoter cloning of the TSACC gene
For the amplification of the regulatory region of Tsacc, genomic DNA was isolated from C2C12
cells using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. PCR was preformed using Tsacc promoter region-specific primer pairs
(Table 1) generated using mouse genomic sequences obtained from the Ensembl database
(www.ensembl.org). PCR was performed using the manufacturer’s protocol (Life Technologies,
Grand Island, NY). PCR products were then ligated into the pGEMT-EZ vector (Promega,
Madison, WI) according to the manufacturer’s protocol and sequenced to confirm amplification
of the predicted target region. Tsacc promoter fragments (~500 and ~1000 base pairs) were sub-
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cloned into the EcoRI and MluI sites of the pSEAP2-Basic reporter plasmid (Clontech, Mountain
View, CA) to create the pSEAP-Tsacc-Pro500 and pSEAP-Tsacc-Pro1000 reporter plasmids and
sequenced to confirm correct orientation.
Reporter Assays
C2C12 myoblast cells were plated in 12-well plates at approximately 75,000 cells/well and
cultured overnight. Cells were transfected at 70-80% confluency using Turbofect Transfection
Reagent (Thermo Scientific, Rockford, IL) and following manufacturer’s protocol. Briefly, a total
of 1μg per well of DNA (250ng/well reporter plasmid, 125ng/well of β-galactosidase (β-gal) and
empty pBluescript vector as filler DNA) was mixed with transfection reagent and allowed to
complex for 20 minutes prior to overlaying the cells. Following transfection, cells were incubated
for 24 hours, and culture media was then changed from DMEM + 10% serum to DMEM + 2%
serum to induce differentiation. Growth media was collected at 24-72 hours after the switch to
differentiation media and tested for SEAP levels using the Phospha-Light SEAP Reporter Gene
Assay Kit and following the manufacturer’s instructions (Life Technologies, Grand Island, NY).
The level of SEAP generated luminescence was assessed using a BioTec Synergy 2 microplate
reader set for an endpoint read with a 2 second integration time. To account for any variation in
transfection efficiency, cells were lysed using Passive Lysis Buffer (Promega, Madison, WI) and
were cleared of cell debris by centrifugation. Cell lysates were incubated with ortho-nitrophenylβ-D-galactopyranoside (ONPG) dissolved in Z Buffer (60mM Na2HPO4·7H2O, 40mM
NaH2PO4·H2O, 10mM KCl, 1mM MgSO4, 50mM β-mercaptoethanol, pH 7.0) overnight at
37°C. Following overnight incubation, β -gal activity was analyzed and used to correct the SEAP
values.
Bioinformatic analysis of Tsacc
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DNA sequences corresponding to the promoter regions of human, rat, and mouse Tsacc
(EnsemblTranscriptID:ENSG00000163467,ENSRNOG00000037552,andENSMUSG000000105
38, respectively) starting at ‐2000 and including the first exon were taken from the Ensembl
database (www.ensembl.org) and analyzed using the Clustal Omega multiple sequence alignment
tool available on the EMBL‐EBI website (https://www.ebi.ac.uk/Tools/msa/clustalo/). The Clustal
Omega

alignment

data

was

then

analyzed

using

Boxshade

version

3.21

(http://www.ch.embnet.org/software/BOX_form.html) that is available on the ExPASy
(www.expasy.org) website. The polypeptide sequences for human, mouse, and rat Tsacc were also
downloaded from Ensembl and aligned using the Clustal Omega alignment tool and shaded with
Boxshade as described for the promoter sequences above.
Reverse transcription quantitative PCR (RT-qPCR)
Total RNA was isolated from proliferating and differentiating C2C12 cells (as described above)
and reverse transcribed using the iScript cDNA synthesis kit according to manufacturer’s protocol
(Bio-Rad, Hercules, CA). The resulting cDNA was mixed with gene specific primers (Table 1)
and iTaq Universal SYBR Green Reaction Supermix according to manufacturer’s instruction and
Tsacc gene expression was then analyzed using a CFX connect Real-Time PCR Detection System
(Bio-Rad, Hercules, CA). Gene expression was analyzed at varying timepoints, each timepoint
was performed in biological triplicate, each individual biological replicate was used for cDNA
amplification in duplicate, and each cDNA amplification replicate was done in technical triplicates
(three biological replicates × two cDNA synthesis replicates × three technical replicates = 18
individual reads per biological sample). Relative gene expression was calculated using the
2−ΔΔCt method and GAPDH as the reference gene.
Protein purification and Western blot analysis
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C2C12 cells were cultured in 10 cm culture plates and Tsacc was exogenously expressed by
transfecting cells with the pCS2(+)-myc-Tsacc full-length (FL) and novel expression plasmids 24
hours post plating. Transfection mix was prepared as previously described above. Cells were
harvested at cell proliferation (DMEM + 10% serum) day 2 and differentiation (DMEM + 2%
serum) days 1, 3, and 5 (PD2, DD1, DD3, and DD5) and stored at -80 C until cell lysis and protein
purification were performed.
Harvested cells were lysed on ice in Universal Lysis Buffer (ULB)(+) (50mM Tris, pH 7.5,
150mM NaCl, 50mM NaF, 0.5% NP-40, with addition of 1mM PMSF, 1mM DTT, 10mM βglycerophosphate, 2mM sodium molbydate and a protease inhibitor cocktail). Cell debris was
cleared through centrifugation and protein concentration was determined using the Quick Start
Bradford 1x Dye reagent following the manufacturer’s instruction (Bio-Rad, Hercules, CA).
Western blots were conducted using 25-100μg of protein separated on a 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) denaturing gel and then transferring to
polyvinylidene fluoride (PVDF) membrane (EMD Millipore, Billerica, MA) overnight. Quality of
the transfer and equal protein loading was verified by Ponceau S staining of the membranes.
Following staining, membranes were blocked using a blocking solution composed of 5% dry milk
dissolved in Tris-buffered saline and 0.05% Tween-20 (TTBS). Westerns blots were probed with
5% dry milk dissolved in Tris-buffered saline and 0.05% Tween-20 (TTBS). The membranes were
probed with anti-myosin heavy chain (MYH1/2/4/6), anti-myogenin, anti-p-ERK, anti-ERK, antiAKT-phospho-S473, anti-AKT, anti-GAPDH, and anti-myc primary antibodies and subsequently
probed with a corresponding species specific HRP-conjugated secondary antibody (Table 2).
Westerns were visualized using ECL Western Blotting Substrate (Thermo Fisher Scientific,
Waltham, MA) following manufacturer’s protocol and imaged using an Amersham Imager 600
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RGB system (GE Healthcare Life Sciences, Marlborough, MA). PVDF membranes were stripped
by incubating the membrane in stripping buffer (10% SDS, 0.5M Tris-HCl pH 6.8, βmercaptoethanol solution) for 20-30 mins and then blocked again, re-probed, and imaged as
described previously.
Table 2. List of antibodies used in this study
Antibody

Source

Catalog #

Dilution

anti-myc

ProteinTech, Rosemont, IL

600032-1g

WB: 1:1000

sc-32732

WB: 1:1000

anti-Myosin Heavy Chain Santa Cruz Biotechnology, Dallas, TX
(MYH1/2/4/6)
anti-myogenin

Santa Cruz Biotechnology, Dallas, TX

sc-12732

WB: 1:1000

anti-GAPDH

ProteinTech, Rosemont, IL

600041-lg

WB: 1:5000

anti-phospho-ERK1/2

Santa Cruz Biotechnology, Dallas, TX

sc-7383

WB: 1:1000

anti-ERK1/2

Santa Cruz Biotechnology, Dallas, TX

sc-94

WB: 1:1000

anti-AKT-phospho-S473

ProteinTech, Rosemont, IL

66444-I-lg

WB: 1:2000

anti-AKT

ProteinTech, Rosemont, IL

602032-lg

WB: 1:5000

sc-2357

WB: 1:5000

PI31450

WB: 1:5000

Mouse anti-rabbit IgG- Santa Cruz Biotechnology, Dallas, TX
HRP
Rabbit anti-mouse IgG- Thermo Scientific, Rockford, IL
HRP (H + L)
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Confocal fluorescent microscopy
C2C12 cells were plated on 3.5cm glass bottom plates at a density of 100,000 cells/plate and
transfected with either 2.5μg pEGFP-Tsacc or empty pEGFP plasmid using Turbofect transfection
reagent at 70-80% cell confluency. At 48 hours post-plating, cells were fixed with 4%
paraformaldehyde dissolved in 0.1 M Sodium Cacodylate and stained with DRAQ5 nuclear stain
(ThermoFisher Scientific, Waltham, MA). Imaging was conducted on an Olympus Fluoview FV1000 confocal fluorescent microscope with a Super Apochromat UPLSAPO 20X objective or a
Super Apochromat UPLSAPO 60X objective. The GFP and DRAQ5 images were then merged
using the open access ImageJ software and utilizing the Open Microscopy Environment BioFormats software plugin tool.
Statistics
Data are presented as the mean ± standard deviation (±SD). Statistical analysis was conducted
using a two-tailed t-test and a difference was considered statistically significant at a P value ≤ 0.05.
Results
Tsacc is induced during neurogenic atrophy.
To better characterize the molecular genetic events of neurogenic atrophy, mouse
gastrocnemius muscle was isolated following 3 days and 14 days of sciatic nerve denervation. The
gene expression profile was analyzed through an Illumina mouse-6 v1.1 expression beadchip
array, as previously described (Furlow et al., 2013). Results from the microarray identified a
significant number of genes that were differentially expressed in response to neurogenic atrophy.
Many of these genes were novel and have not been previously implicated in atrophy or
characterized in skeletal muscle, with Tsacc being among these novel genes. Microarray analysis
revealed that Tsacc is expressed at relatively low levels in control muscle tissue and is significantly
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induced in response to neurogenic atrophy 14 days post-denervation (Fig 7A and 7B).
Additionally, the microarray examined if MuRF1 expression had an effect on Tsacc expression.
Both MuRF1-null mice and wild-type mice displayed relatively similar Tsacc expression profiles
at both 3 days and 14 days post-denervation (Fig 7A and 7B).

Figure 7. Tsacc is induced in response to denervation-induced skeletal muscle atrophy.
Whole genome expression analysis was conducted on triceps surae muscle from wild-type (WT)
and MuRF1-null (KO) control mice after 3 days (3D) and 14 days (14D) post-denervation (DEN).
Tsacc expression was unchanged in WT and KO mice at (A) 3 days post-denervation, but increased
significantly at (B) 14 days post-denervation in the wild-type and MuRF1-null animals. Each
condition represents the average expression from three animals and error bars represent ± SD. Grey
bars represent the controls (Con) and black bars represent denervation (Den). Significant
difference between denervated mice and control mice in the same group (*:P < 0.01).
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Tsacc expression is regulated by Myogenic Regulatory Factors
To gain insight into how Tsacc is regulated transcriptionally in muscle cells, 500 and 1000 base
pairs of the promoter were amplified using the primers listed in Table 1. The fragments were then
fused to a secreted alkaline phosphatase (SEAP) reporter gene to create the pSEAP-Tsacc-Pro500
and pSEAP-Tsacc-Pro1000 reporter constructs. The Tsacc reporter gene constructs were
transfected into C2C12 mouse myoblasts and SEAP assays were performed 48h after the switch to
differentiation media. Both promoter fragments showed higher expression compared to the empty
plasmid alone (Fig. 8A and 8B). To further analyze the transcriptional activity of Tsacc, cells were
co-transfected with a MyoD expression plasmid along with the Tsacc reporter gene constructs.
MyoD, a myogenic regulatory factor (MRF), is a known transcription factor that is muscle specific
and has a role in myogenesis. Overexpression of MyoD significantly induced the transcriptional
activity of both the pSEAP-Tsacc-Pro500 and pSEAP-Tsacc-Pro1000 reporter constructs (Fig. 8A
and 8B). Importantly, bioinformatic analysis of the promoter region of Tsacc revealed four
predicted MyoD binding sites within the first 500 bps upstream of the start of transcription (Fig
8C).
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Figure 8. Cloning and analysis of the proximal regulatory region of the Tsacc gene locus.
Secreted Alkaline Phosphatase (SEAP) reporter gene analysis of culture media from C2C12 cells
transfected with either the (A) pSEAP-Tsacc-Pro500 or the (B) pSEAP-Tsacc-Pro1000 reporter
constructs with or without a MyoD expression plasmid. The empty pSEAP vector served as a
negative control. The culture media was changed to low serum media 24 hours post-transfection
to induce differentiation and the culture media was then sampled 48 hours post-media change. The
SEAP numbers were normalized to β-galactosidase activity to correct for variations in transfection
efficiency. Each condition was performed in triplicate and each experiment was repeated at least
three times (n=3). The graphs are of a representative experiment and values correspond to the mean
relative light unit (RLU) values ± SD. Significant differences between the activities of the
pSEAP2-Tsacc-Pro reporter constructs with and without MyoD ectopic expression (* = P ≤ 0.05).
(C) Schematic and sequence alignment of the Tsacc regulatory region. Promoter sequences from
mouse, rat, and human Tsacc (2000 base pairs upstream of the transcription site (+1) through the
first exon) were downloaded from the Ensembl database (www.ensembl.org) and aligned using
the ClustalW algorithm. Regions highlighted in black show identical sequences between the three
species. Approximate positions of potential transcription factor binding sites are highlighted in the
alignment: AP-2 Consensus Binding Element (blue trapezoid); Oct1 Binding Element (yellow
triangle); MyoD Binding Element (red diamond); NF-κB Consensus Binding Element (green
square).
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Tsacc is alternatively spliced in muscle cells
To better characterize the role of Tsacc in skeletal muscle, cloning of the Tsacc gene from
cultured muscle cells resulted in the identification of a novel transcript of Tsacc. The novel Tsacc
transcript contains an extra exon compared to the full-length transcript of Tsacc (Fig. 9), giving
rise to a protein that is different in size. The novel Tsacc protein is predicted to be 49 amino acids
shorter than the FL Tsacc protein as a result of the extra exon (Fig. 9).

Figure 9. Schematic of the validated Tsacc transcript and a newly discovered Tsacc novel
transcript. The boxes represent exons, and the connecting lines represent introns. An extra exon
which produces a shorter 75 amino acid protein is observed in the novel Tsacc transcript compared
to the full-length transcript. This expanded exon region contains classic intron and exon boundaries
which are highlighted in red.
Tsacc is upregulated during muscle cell differentiation
To analyze the transcriptional expression of Tsacc during muscle cell differentiation. C2C12
cells were cultured, differentiated, and harvested over a time course of proliferation day 2 (PD2),
differentiation day 2 (DD2), and differentiation day 7 (DD7). RNA was isolated and used for
analysis of Tsacc expression by reverse transcription quantitative polymerase chain reaction (RTqPCR). Three primer pairs spanning different regions of the Tsacc gene were used. Primer pair
one spanned through the 5’ untranslated region (5’-UTR), primer pair two spanned across the exon
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2 and exon 3 boundary, and primer pair three spanned across the exon 2 and exon 4 boundaries
(Table 1). The qPCR analysis confirmed that Tsacc is expressed in muscle cells and increases as
cells differentiate, with the lowest expression during proliferation and highest expression during
late differentiation (Fig. 10).

Figure 10. qPCR analysis of Tsacc expression in C2C12 cells. Three primer pairs spanning three
different regions of the Tsacc mRNA were used for qPCR. RNA was extracted from C2C12 cells
at proliferation day 2 (PD2), differentiation day 2 (DD2), and differentiation day 7 (DD7). cDNA
samples were subsequently analyzed by qPCR and normalized in comparison to PD2. For primer
pairs 1 (A), 2 (B), & 3 (C), the relative expression of Tsacc was found to increase from PD2 to
DD7 in C2C12 cells. Relative expression of Tsacc was normalized to GAPDH expression using the
2-ΔΔCT method.
Tsacc full-length and novel proteins display distinct localization patterns in muscle cells.
To elucidate the sub-cellular location of Tsacc in muscle cells, pEGFP-Tsacc-FL and pEGFPTsacc-novel expression plasmids were created and transfected into C2C12 cells. Tsacc-FL
displayed localization that was specific to the cytoplasm and was nuclear excluded (Fig. 11), while
the Tsacc-novel displayed a diffuse pattern, localizing in both the cytoplasm and the nucleus (Fig.
12). These distinct localization patterns are likely due to the 49 amino acid region that is missing
in the Tsacc-novel isoform.
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Figure 11. Tsacc-FL localizes to the cytoplasm of muscle cells. C2C12 cells transfected with full
length Tsacc-GFP displayed cytoplasmic localization (Panels 1 and 4). Cells transfected with fulllength Tsacc-GFP were stained with Draq5 nuclear stain, visualizing the nuclei of proliferating
myoblasts (Panels 2 and 5). Overlay of Draq5 stained and full-length Tsacc-GFP expressing cells
displayed nuclear exclusion of Tsacc in muscle cells (Panels 3 and 6).

Figure 12. Tsacc-novel localizes to both the cytoplasm and nucleus of muscle cells. C2C12 cells
transfected with novel Tsacc-GFP displayed cytoplasmic localization (Panels 1 and 4). Cells
transfected with novel Tsacc-GFP and stained with Draq5 nuclear stain, visualizing the nuclei of
proliferating myoblasts (Panels 2 and 5). Overlay of Draq5 stained and novel Tsacc-GFP
expressing cells displayed both cytoplasmic and nuclear localization of the novel Tsacc protein in
muscle cells (Panels 3 and 6).
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Ectopic expression of Tsacc-FL attenuates muscle cell differentiation while Tsacc-novel
overexpression has no effect on muscle cell differentiation.
To better characterize the role of Tsacc in skeletal muscle, a myc-tagged Tsacc expression
plasmid was constructed and used in all Western blot analyses due to the novelty of this gene and
the unavailability of a commercial antibody. In frame fusion of the Tsacc cDNA with the myc tag
was confirmed by sequencing and overexpression in C2C12 cells using the myc-tagged pCS2(+)myc-Tsacc-FL and pCS2(+)-myc-Tsacc-Novel expression plasmids. Protein was then isolated
from transfected cells and Western blot analysis was performed using increasing concentrations
(25µg, 50µg, and 75µg) of protein homogenates isolated from the Tsacc overexpressing cells and
membranes were probed for myc-tagged Tsacc using an anti-myc antibody (Fig. 13).

Figure 13. Validation of myc-tagged Tsacc-FL and Tsacc-novel overexpression in C2C12
cells. C2C12 cells were transfected with a myc-tagged Tsacc-FL or myc-tagged Tsacc-novel
expression plasmid and Tsacc overexpression was confirmed by probing with an anti-myc
antibody.
To evaluate if Tsacc impacts muscle cell differentiation, C2C12 cells transfected with myctagged Tsacc-FL or myc-tagged Tsacc-novel expression plasmids were harvested over a time
course that included 2 days of proliferation (PD2) and 1, 3, and 5 days of differentiation (DD1,
DD3, and DD5, respectively). Protein was isolated from cells and evaluated for the expression of
known markers of muscle cell differentiation, including myosin heavy chain (MyHC) and
myogenin. Western blot analysis revealed that Tsacc-FL overexpression significantly decreased
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both myogenin and MyHC expression at all differentiation timepoints (Fig. 14A). To verify
inhibition of muscle differentiation, Tsacc-FL was overexpressed in biological quadruplicates and
harvested at 3 days post-differentiation. Lysates were evaluated by Western blot and myogenin
and MyHC expression levels were found to be significantly repressed in lysates isolated from cells
ectopically expressing Tsacc-FL (Fig. 14B). Interestingly, overexpression of Tsacc-Novel in
muscle cells appears to have very little effect on either MyHC or myogenin levels (Fig. 15A). This
observation was further examined by overexpressing Tsacc-novel in biological quadruplicates and
harvesting C2C12 cells at differentiation day 1. Lysates were evaluated by Western blot and
myogenin expression levels were not found to be significantly repressed in lysates isolated from
cells ectopically expressing Tsacc-novel (Fig. 15B) Tsacc-novel effects on MyHC were not
analyzed in the quadruplicates at differentiation day 1, since MyHC expression is usually very low
during early differentiation (Fig. 15B). All blots were Ponceau S stained prior to probing to
confirm transfer efficiency and equal protein loading (Fig. 14 and 15). GAPDH protein levels were
also analyzed to confirm that protein levels were equally loaded for all samples (Fig. 14 and 15).
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Figure 14. Ectopic expression of Tsacc-FL attenuates muscle cell differentiation. C2C12 cells
were transfected with the pCS2(+)-myc-Tsacc-FL expression plasmid. Cells were maintained in
media supplemented with 10% serum for the proliferation timepoints and switched to DMEM
supplemented with 2% serum to induce differentiation. Cells were harvested at proliferation day
2 (PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis of the
differentiation markers Myosin Heavy Chain (MyHC) and myogenin showed significantly lower
levels of expression at DD3 and DD5 in response to Tsacc-FL overexpression. (B) Western blot
analysis of MyHC and myogenin using protein homogenates from C2C12 cells differentiated for 3
days. C2C12 cells were transfected with the myc-tagged Tsacc-FL expression plasmid in biological
quadruplicates, maintained in proliferation media, and then switched to differentiation media (2%
serum) for 3 days.
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Figure 15. Ectopic expression of Tsacc-novel does not appear to affect muscle cell
differentiation. C2C12 cells were transfected with a pCS2(+)-myc-Tsacc-novel expression
plasmid. Cells were maintained in DMEM supplemented with 10% serum for the proliferation
timepoints and switched to DMEM supplemented with 2% serum to induce differentiation. Cells
were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and 5 (DD1, DD3, DD5).
(A) Western blot analysis revealed no significant change in Myosin Heavy Chain (MyHC) and
myogenin expression in response to Tsacc-novel overexpression. (B) C2C12 cells were transfected
with the myc-tagged Tsacc-novel expression plasmid in biological quadruplicates, maintained in
proliferation media, and then switched to differentiation media (2% serum) for 1 day. Western blot
analysis of myogenin using protein homogenates from C2C12 cells at differentiation day 1.
Overexpression of Tsacc may inhibit AKT activation
The effect of Tsacc overexpression on AKT signaling was evaluated by Western blot analysis
over a cell differentiation time course. Cells overexpressing either myc-tagged Tsacc-FL or myctagged Tsacc-novel showed a reduction in p-AKT levels (Fig 16A and 16B). Whole AKT levels
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were also assessed by Western blot utilizing a mouse monoclonal antibody and the results show a
small decrease in whole AKT protein levels between control cells and cells overexpressing TsaccFL or Tsacc-novel (Fig 16A and 16B).

Figure 16. Ectopic expression of either Tsacc-FL or Tsacc-Novel appears to inhibit AKT
activation in muscle cells. C2C12 cells were transfected with either the myc-tagged Tsacc-FL or
myc-tagged Tsacc-novel expression plasmids and harvested at proliferation day 2 (PD2) and
differentiation days 1, 3, and 5 (DD1, DD3, DD5). (A) Western blot analysis showed a reduction
in phosphorylated AKT with Tsacc-FL overexpression at all differentiation timepoints. (B)
Western blot analysis showed a reduction in phosphorylated AKT with Tsacc-novel
overexpression at DD1 and DD3.
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Discussion
Previous studies have focused on the characterization of Tsacc in spermatids as it is believed
to play a vital role in mammalian spermatogenesis. Characterization of Tsacc and its relation to
skeletal muscle atrophy became of interest after the microarray data revealed differential gene
expression patterns between control and denervated muscle (Furlow et al., 2013). Tsacc expression
appeared to be unchanged in both wild-type and MuRF1 KO mice 3 days post-denervation but was
significantly induced by 14 days post-denervation, suggesting that Tsacc is induced during “longterm” neurogenic atrophy (Fig. 7).
This investigation is the first study to characterize Tsacc in the context of skeletal muscle. While
cloning the Tsacc gene from cultured muscle cells for its characterization, a novel transcript of
Tsacc was identified. This transcript is 49 amino acids shorter than the full length (FL) Tsacc
protein and has not been previously identified (Fig. 9). The identification of this novel transcript
altered the objective of this study to not only characterize Tsacc role in skeletal muscle but to also
determine whether alternative splicing altered protein function. Therefore, both full length (FL)
and novel transcripts were further studied, and differences were evaluated.
Tsacc expression was evaluated through RT-qPCR analysis of C2C12 myoblast. Data from these
experiments showed that Tsacc mRNA expression levels increased as muscle cells underwent
differentiation, with the highest expression levels occurring during late differentiation (DD7) and
the lowest expression occurring during proliferation (PD2) (Fig. 10). Additionally, using a reporter
gene system, Tsacc was confirmed to be transcriptionally active in skeletal muscle and was shown
to be highly inducible by myogenic regulatory factors (MRFs), specifically MyoD. MRF’s
modulate activity of muscle-specific genes through binding of Ebox elements. Bioinformatic
analysis of the Tsacc proximal regulatory region resulted in the identification of four potential

29

MyoD binding sites located in the proximal promoter region of Tsacc (Fig. 8). MyoD, along with
myogenin, act as important biomarkers of muscle cell commitment and differentiation and are
upregulated during myogenesis and neurogenic skeletal muscle atrophy (Hernandez et al., 2017,
Furlow et al., 2013). This further supports our findings that Tsacc increases in expression during
differentiation is likely due to regulation by MRFs, suggesting that Tsacc expression is sensitive
to changes in the muscle cell environment.
The relationship between MRFs and Tsacc was further evaluated through Western blot analysis.
Tsacc FL overexpression was shown to have an inhibitory effect on muscle cell differentiation,
seen by a reduction in both myosin heavy chain (MyHC) and myogenin protein levels in cells
overexpressing the FL transcript of Tsacc (Fig. 14). Interestingly, this inhibition of differentiation
was not observed in cells that overexpressed the novel transcript of Tsacc. In cells overexpressing
the novel Tsacc transcript, myogenin and MyHC protein levels appeared to be unchanged
compared to control cells (Fig. 15). Although this data provides evidence that Tsacc may play a
role in proper muscle cell differentiation, it also suggests a more complex interaction where
alternative splicing might affect Tsacc intracellular function.
To gain better insight into Tsacc function, signal transduction pathways that are known
modulators of muscle mass and size were evaluated in response to Tsacc overexpression. Since
atrophying muscle tissue tend to exhibit a reduction in AKT pathway activity that is typically
indicated by a reduction in phosphorylated-AKT levels, the effect of Tsacc overexpression on
AKT and p-AKT levels was evaluated by Western blot analysis. The ectopic expression of TsaccFL or Tsacc-Novel in C2C12 cells appears to negatively modulate phosphorylation levels of AKT
(Fig. 16). This is interesting due to the fact previous genes characterized in our lab and identified
as denervation-induced genes have also been found to modulate the AKT pathway by either
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directly altering p-AKT levels or by altering the activity downstream targets such as GSK-3β or
mTOR (Cooper et al., 2020b, Smith et al., 2021).
Tsacc characterization was further evaluated at the subcellular level by confocal fluorescent
microscopy. Confocal microscopy revealed that Tsacc-FL localization was exclusive to the
cytoplasm while the Tsacc-novel protein transcript displayed a diffuse localization pattern,
exhibiting localization in both the cytoplasm and nucleus of skeletal muscle cells (Fig. 11 and 12).
This data further suggests that alternative splicing plays an important role in the function of Tsacc
and suggesting that the role of Tsacc in skeletal muscle might be fairly complex and dependent on
which transcript is predominantly expressed. Additional research is currently underway to further
characterize the role of Tsacc in the MAP Kinase and AKT signaling pathways in muscle cells.
Future Directions
Characterize the role of Tsacc in the MAP kinase signaling pathway.
The mitogen-activated protein kinase (MAPK) signaling pathway is an important pathway for
muscle cell growth and development and is made up of four distinct branches, which includes
extracellular signal-related kinase 1/2 (ERK1/2), p38, c-Jun N-terminal kinase (JNK), and ERK5
(Cargnello and Roux, 2011). Therefore, investigating the effect of Tsacc overexpression on MAPK
signaling and determining which of these branches might be regulated by Tsacc is of particular
interest. Based on previous studies from our lab, we hypothesize that Tsacc may target the ERK1/2
branch in muscle cells (Haddock et all, 2019, Hayes et al., 2019, Cooper et al., 2020a, Labuzan et
al., 2020). The ERK1/2 branch modulates muscle cell development and shows variation in its
activity, with ERK1/2 phosphorylation being highest during proliferation and late differentiation
(Bennett and Tonks, 1997). This study suggests that Tsacc regulation of the MAPK pathway is
potentially complex, with preliminary data showing that the overexpression of Tsacc-novel in
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C2C12 cells appears to increase p-ERK1/2 levels during proliferation and early differentiation (Fig.
17). This is of significance since it implies that Tsacc may help modulate ERK1/2 activity and
regulate muscle cell differentiation, and this effect may be dependent on alternative splicing.
Preliminary experiments looking at ERK1/2 activity in response to Tsacc-FL overexpression are
currently underway. A potential role for Tsacc in MAP kinase signaling will also be further
evaluated through the overexpression of either novel Tsacc or FL Tsacc in C2C12 cells and
monitoring AP-1 reporter gene activity over a time course as cells differentiate from myoblasts to
myotubes.

Figure 17. Ectopic expression of Tsacc-novel appears to upregulate the ERK1/2 branch of
the MAPK signaling cascade. C2C12 cells were transfected with the myc-tagged Tsacc-novel
expression plasmid. Cells were maintained in DMEM supplemented with 10% serum for the
proliferation timepoints and switched to DMEM supplemented with 2% serum to induce
differentiation. Cells were harvested at proliferation day 2 (PD2) and differentiation days 1, 3, and
5 (DD1, DD3, DD5). Western blot analysis of ERK1/2 and phospho-ERK1/2 show an increase in
expression at PD2 and DD1 in response to Tsacc-novel overexpression. GAPDH and Ponceau S
stain were used to confirm equal protein loading across all samples.
Further analyzing the role Tsacc in MAPK signaling is of importance since it will allow for better
understanding of the significance of Tsacc alternative splicing and help clarify if alternative
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transcripts of Tsacc influence muscle through differential regulation of signaling pathways that are
known to play an important role in muscle cell development, growth, and atrophy. To date, this
study has shown that Tsacc plays a role in skeletal muscle and that its function might be more
complex than originally thought due to alternative splice variants produced by this gene.
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